A functional disulfide bond in both the HIV envelope glycoprotein, gp120, and its immune cell receptor, CD4, is involved in viral entry, and compounds that block cleavage of the disulfide bond in these proteins inhibit HIV entry and infection. The disulfide bonds in both proteins are cleaved at the cell surface by the small redox protein, thioredoxin. The target gp120 disulfide and its mechanism of cleavage were determined using a thioredoxin kinetic trapping mutant and mass spectrometry. A single disulfide bond was cleaved in isolated and cell surface gp120, but not the gp160 precursor, and the extent of the reaction was enhanced when gp120 was bound to CD4. The Cys32 sulfur ion of thioredoxin attacks the Cys296 sulfur ion of the gp120 V3 domain Cys296-Cys331 disulfide bond, cleaving the bond. Considering that V3 sequences largely determine the chemokine receptor preference of HIV, we propose that cleavage of the V3 domain disulfide, which is facilitated by CD4 binding, regulates chemokine receptor binding. There are 20 possible disulfide bond configurations, and, notably, the V3 domain disulfide has the same unusual –RHStaple configuration as the functional disulfide bond cleaved in CD4.

The human immunodeficiency virus (HIV) is the agent responsible for AIDS. The HIV envelope glycoprotein (env) is translated as a single polypeptide chain (gp160) that is proteolytically cleaved by host cell subtilisins into two noncovalently associated fragments, the surface glycoprotein subunit (gp120) and the transmembrane (gp41) subunit that is anchored in the viral membrane (1). env is a trimer of gp120/gp120 heterodimers on the viral surface that is activated by sequential binding to CD4 and chemokine receptor CXCR4 or CCR5 on susceptible cells. gp120 is thought to dissociate from gp41, which allows the fusion peptide to be inserted into the target membrane. The end result is formation of a six-helix bundled gp41 ectodomain that drives the membrane merger and eventual fusion (2). Functional disulfide bonds in both HIV gp120 and immune cell CD4 are involved in viral entry, and compounds that block cleavage of these disulfide bonds inhibit HIV entry and infection (3–7).

The disulfide bond in the second extracellular immunoglobulin-like domain of CD4, Cys130-Cys159, is reduced on the T cell surface by thioredoxin, which leads to formation of disulfide-linked homodimers (7–9). Domain swapping of D2 has been identified as the most likely mechanism for formation of the dimer, where the domain-swapped dimer is held together by two disulfide bonds between Cys130 in one monomer and Cys159 in the other one (10, 11). Inhibiting CD4 dimer formation by mutating residues in the D1 and D4 domains enhances viral entry (12), whereas blocking dimer formation by ablating the D2 disulfide bond markedly impairs the CD4 immune co-receptor function (10).

Either one or two of the nine disulfide bonds in gp120 is cleaved during viral and target cell membrane fusion (3–6, 13). It has been hypothesized that reduction of the gp120 disulfide bond(s) facilitates unmasking of the gp41 fusion peptide and its insertion into the target cell membrane. The thiol content of gp120 increases from 0.5–1 to 4 mol of thiol/mol gp120 following interaction of gp120 with cells expressing CD4 and CXCR4 (3). This redox change in gp120 is independent of the chemokine receptor usage of the virus (4). Cleavage of the gp120 disulfide bond is critical for env-mediated cell-cell fusion and HIV entry and infection as these processes are blocked by both small molecule and protein inhibitors of cell surface oxidoreductases (3–6). The oxidoreductase that has received the most attention is protein disulfide isomerase (14). Protein disulfide isomerase co-precipitates with both soluble and cellular CD4 (4), and it has been proposed that gp120 induces assembly of protein disulfide isomerase, CD4, and chemokine receptor into a tetramolecular protein complex serving as a portal for viral entry (5).

The gp120 disulfide(s) can be reduced by protein disulfide isomerase (3, 4), thioredoxin (8), or glutaredoxin-1 (13). This observation implies that the gp120 disulfide bond(s) must have a high redox potential, as protein disulfide isomerase is a poor reductant with a standard redox potential of ~175 mV (15). A high redox potential implies that the gp120 disulfide(s) is primed for reduction. Thioredoxin, a small disulfide bond reductant secreted by a variety of cells including CD4+ cells (7, 16), has been reported to be a more efficient gp120-reducing agent than protein disulfide isomerase (8).

The question we have asked in this study is what disulfide bond(s) is reduced in gp120 during viral entry. This has been...
accomplished by mechanism-based kinetic trapping of the gp120 disulfide bond with thioredoxin.

**EXPERIMENTAL PROCEDURES**

**Proteins**—Full-length wild type and C35S mutant human thioredoxin-1 cDNAs in the *Escherichia coli* pQE-60 expression vector were kindly provided by Dr. Tobias Dick, German Cancer Research Center, Heidelberg, Germany. The recombinant wild type human thioredoxin-1 (wtTrx) or C35S mutant (C35STrx) proteins were produced as described (9, 17).

The following HIV gp120 proteins were obtained through the National Institutes of Health AIDS Reference and Reagent Program: HIV-1Bal gp120 (laboratory isolate), HIV-1CN54 gp120 (Clade C), HIV-1V3TH975 gp120 (Clade E). The laboratory isolate was expressed in insect cells. A recombinant protein containing the four immunoglobulin-like domains (sCD4) was provided by the NIH AIDS Research and Reference Reagent Program.

**Mechanism-based Kinetic Trapping of Purified gp120 Protein with Human Thioredoxin**—wtTrx or C35STrx (4 μM) was incubated with HIV-1Bal gp120 (4 μM) in 0.1 M Na2PO4 buffer, pH 7.0, containing 0.1 mM EDTA for 1 h at 25 °C. On some occasions, incubations were in the presence of sCD4 (4 μM). Samples of the reactions were resolved on NuPAGE Novex 4–12% BisTris gel (Invitrogen) with MOPS running buffer under nonreducing conditions and transferred to polyvinylidene difluoride membrane. Proteins were detected by Western blotting using either 1 μg ml1 anti-human thioredoxin monoclonal antibody (BD Pharmingen) or 1 μg ml1 anti-gp120/160 rabbit polyclonal antibody (Immune Technology) with MOPS running buffer under nonreducing conditions and transferred to polyvinylidene difluoride membrane. Proteins were detected by Western blotting using either 1 μg ml1 anti-human thioredoxin monoclonal antibody (BD Pharmingen) or 1 μg ml1 anti-gp120/160 rabbit polyclonal antibody (Immune Technology) and a 1:1,000 dilution of rabbit anti-mouse or swine anti-rabbit peroxidase-conjugated antibodies (Dako, Carpinteria, CA). Chemiluminescence films were analyzed using a GS-700 Imaging Densitometer and Multi-Analyst software (Bio-Rad).

**ELISA for Reduction of gp120 by Thioredoxin**—HIV-1Bal gp120 (100 μl of 2 μg ml1 in 0.1 M NaHCO3, pH 9.6 buffer) was adsorbed to Maxi-Sorp 96-well plates (Nunc, Roskilde, Denmark) for 60 min, and the wells were blocked with 5% skim milk in phosphate-buffered saline (PBS) containing 0.2% Tween 20 for 60 min at 37 °C. wtTrx (4 μM in PBS /Tween) was added to wells and incubated for discreet times at 25 °C. The unpaired cysteine thiols in gp120 were alkylated by incubation with 2 μM 3-(N-maleimidylpropionyl)biocytin (Molecular Probes, Eugene, OR) for 30 min at 25 °C. The wells were washed four times with PBS/Tween and incubated with 100 μl of 1:1,000 dilution of StreptABComplex/HRP (Dako) in PBS/Tween for 30 min at 25 °C with orbital shaking. Wells were washed three times, and the bound peroxidase was detected as described previously (18).

**Cell-Cell Fusion Assay**— Luciferase reporter assays for cell-to-cell fusion were performed as described (20) with minor modifications. HEK target cells were co-transfected with 0.25 μg pTMLuc (a bacteriophage T7 promoter-driven firefly luciferase expression vector (21), 0.25 μg of pcCXCR4 (22), and 0.25 μg of pcDNA3-CD4 and incubated for 24 h at 37 °C and 5% CO2. HEK effector cells were co-transfected with 0.25 μg of env vector p89.6 and 0.125 μg of pCAGT7 (a T7 RNA polymerase expression vector) (23) and incubated for 48 h at 37 °C and 5% CO2. The transfected target cells were washed twice in serum-free medium, harvested with PBS containing 0.05% EDTA, resuspended in 1 ml of complete medium, plated onto effector cells that had been washed twice with PBS, and co-cultured for 24 h at 37 °C and 5% CO2. The fusion of effector and target cells was determined using the Luciferase Reporter Assay System (Promega) and expressed as relative light units.

**Mutagenesis of HIV-1 gp160**—pcDNA3.1 plasmid containing the env region of the HIV-1 clone 89.6 was provided by Dr. Pantelis Pombourious, Virology Unit, St. Vincent’s Institute of Medical Research, Victoria, Australia. The pair of cysteine residues that form the disulfide bond in the V1/V2 stem (Cys126 and Cys196), the V3 domain (Cys326 and Cys396), the V3 domain (Cys385 and Cys418) were individually mutated to alanine residues. Site-directed mutagenesis was performed using the QuikChange Site-directed Mutagenesis kit (Integrated Sciences, La Jolla, CA) following the manufacturer’s instructions. All primers were purchased from Sigma: C216A, 5’-GATAAATTTACCCATGCGTTCCT-3’; C196A, 5’-GTTTAAATAGTGGCACAAC-3’; C296A, 5’-CTGTGATATAATAGCCCA-3’; C396A, 5’-GATAAATTACCCATGCGTTCCT-3’; C331A, 5’-GATAAAATTTTCTAGCACAATGAG-3’; C385A, 5’-GATAAATTTACCCATGCGTTCCT-3’; and C418A, 5’-GATAAATTTTCTAGCACAATGAG-3’. All mutations were confirmed by sequencing.
were confirmed by automatic sequencing (ABI-377 Automatic Sequencer).

Mass Spectrometry—HIV-1_BaL gp120 (4 μM) was left untreated or reacted with C35STrx (4 μM) in 0.1 M Na2PO4, pH 7.0, buffer containing 0.1 mM EDTA for 1 h at 25 °C. Unpaired cysteine thiols in the proteins were alkylated with 10 mM iodoacetamide for 30 min at 25 °C in the dark, and the unreacted iodoacetamide was removed from the solution using Zeba spin desalting columns (Thermo Scientific). The gp120 was denatured for 10 min at 100 °C in 50 mM Na2PO4, pH 7.5, buffer containing 1 M guanidine HCl and 10 mM dithiothreitol. The solution was cooled, and peptide-protein was digested with chymotrypsin (500 units/ml; Sigma-Aldrich) to remove the gp120 N-glycans. The samples were incubated at 37 °C for 5 h, and the reaction was stopped by heating to 100 °C for 5 min. The protein was digested with chymotrypsin (5 μg/ml; Roche Applied Science) for 5 h at 25 °C in 50 mM Na2PO4, pH 7.5, buffer containing 10 mM CaCl2, and the reaction was stopped with 10% acetic acid.

Digested peptides were separated by nano-LC using an Ultimate 3000 HPLC and autosampler system (Dionex, Amsterdam, The Netherlands), and samples were loaded onto a fritless nano column (75 μm × 10 cm) containing C18 media (5 μm, 200 Å Magic, Michrom). Peptides were eluted using a linear gradient of H2O:CH3CN (64:36, 0.1% formic acid) to H2O:CH3CN (64:36, 0.1% formic acid) at 250 nl/min over 60 min. Positive ions were generated by electrospray and analyzed in a LTQ FT Ultra (Thermo Electron, Bremen, Germany) mass spectrometer operated in data-dependent tandem MS acquisition mode. Mass spectral data were searched using Mascot (version 2.2; Matrix Science) against the nonredundant database from NCBI (June 3, 2010). Search parameters were: precursor tolerance 10 ppm and product ion tolerances of ±0.4 Da. Met-O, Cys-carboxyamidomethyl and Asn-deamination were selected as variable modifications with XCalibur Qual Browser software (version 2.0.7; Thermo). The area extracted ion chromatograms were generated using the XCalibur Qual Browser software. The area extracted ion chromatograms were generated using the XCali bur Qual Browser software. The area extracted ion chromatograms were generated using the XCalibur Qual Browser software. It was important to determine whether the phenomena observed in assays with purified gp120 and sCD4 (Figs. 1 and 2) also occurred on the cell surface with native full-length proteins. HEK cells were transiently transfected with either HIV-1 89.6 env or CD4, and reaction of C35STrx with the gp120-expressing cells was measured in the absence or presence of CD4-expressing cells. C35STrx reacted with a single disulfide bond of cell surface gp120, but not with unprocessed gp160, and the reaction was enhanced by the presence of CD4-expressing cells (Fig. 3A). These results parallel those observed using the purified proteins and also indicate that oxidoreductases such as thioredoxin reduce the disulfide bond in gp120 but not its gp160 precursor.

RESULTS

The disulfide bond or bonds cleaved in gp120 by oxidoreductases during fusion of the viral and cell membranes was determined using a thioredoxin trapping mutant, in which the active site cysteine (Cys35) that normally resolves the mixed disulfide has been mutated to serine (9, 17). Replacement of Cys35 with serine stabilizes the covalent intermediate. Wild-type thioredoxin (wtTrx) and C35S trapping mutant (C35STrx) were expressed in E. coli and purified to homogeneity (Fig. 1A). A small amount of thioredoxin dimer, which is inert as a redox catalyst, was present in both preparations.

Mechanism-based Kinetic Trapping of a gp120 Disulfide Bond with Human Thioredoxin—Incubation of purified gp120 with wtTrx or C35STrx resulted in a single complex of gp120 with the thioredoxin-trapping mutant but not with wtTrx (Fig. 1B). The complex was identified by blotting with either thioredoxin or gp120 antibodies (Fig. 1B). The size of the complex (~140 kDa) is consistent with reaction of one molecule of C35STrx with one molecule of gp120, indicating that one gp120 disulfide bond has been reduced. As anticipated, the complex is disulfide-linked as it resolved upon reduction with 20 mM dithiothreitol. C35STrx cleaved a single disulfide bond in four different gp120 isoforms; a laboratory isolate (HIV-1_BaL gp120), two Clade C isoforms (HIV-1_CNS4 and HIV-1_EA2_6551), gp120, and a Clade E isoform (HIV-1_B13497_Ep120) (Fig. 1C). This result indicates that the gp120 disulfide bond targeted by oxidoreductases is present and available in different isoforms of the protein.

Binding of gp120 to CD4 Enhances Cleavage of the gp120 Disulfide Bond by Thioredoxin—Interaction of gp120 with CD4 results in a conformational change in gp120 (24), which suggests that CD4 binding may influence the accessibility or redox potential of the gp120 disulfide bond cleaved by oxidoreductases. This was tested in two different assays, an ELISA that measures reduction of disulfide bond(s) in gp120 and using the C35STrx trapping mutant.

gp120 was coated onto ELISA plate wells and incubated with wtTrx and/or recombinant sCD4 consisting of the four extracellular immunoglobulin domains. Reduction of disulfide bond(s) in gp120 was measured by labeling with a biotin-linked maleimide and detection with avidin-peroxidase. wt-Trx reduced one or more disulfide bonds in gp120, which was significantly enhanced by the presence of sCD4 (p < 0.001) (Fig. 2A). The assay was specific, as negligible labeling of gp120 was observed in the absence of thioredoxin without or with sCD4. sCD4 also enhanced the reaction of C35STrx with gp120 (Fig. 2B).

Thioredoxin Cleaves the gp120 Disulfide Bond on the Cell Surface, and Cleavage Is Enhanced by CD4-expressing Cells—It was important to determine whether the phenomena observed in assays with purified gp120 and sCD4 (Figs. 1 and 2) also occurred on the cell surface with native full-length proteins. HEK cells were transiently transfected with either HIV-1 89.6 env or CD4, and reaction of C35STrx with the gp120-expressing cells was measured in the absence or presence of CD4-expressing cells. C35STrx reacted with a single disulfide bond of cell surface gp120, but not with unprocessed gp160, and the reaction was enhanced by the presence of CD4-expressing cells (Fig. 3A). These results parallel those observed using the purified proteins and also indicate that oxidoreductases such as thioredoxin reduce the disulfide bond in gp120 but not its gp160 precursor.

Reduction of the gp120 Disulfide Bond by Oxidoreductases Such as Thioredoxin Is Not Rate-limiting for env-mediated Cell-Cell Fusion—A feature of HIV infection is syncytium formation between infected cells and CD4+ cells. HEK target
cells were co-transfected with bacteriophage T7 promoter-driven firefly luciferase, CXCR4 chemokine receptor, and CD4. HEK effector cells were co-transfected with HIV-1 89.6 env and T7 RNA polymerase. The transfected target cells were plated onto effector cells in the absence or presence of wtTrx or C35STrx and co-cultured for 24 h. Fusion of effector and target cells was determined by luciferase activity. There was no detectable luciferase activity when cells lacking either gp120 or CD4 were used. The presence of micromolar concentrations of the thioredoxins had no significant effect on the extent of cell-cell fusion (Fig. 3B). This result suggests that cleavage of the gp120 disulfide bond is not rate-limiting in the cell-cell fusion process. If it were rate-limiting, then addition of exogenous thioredoxin would have been expected to enhance fusion.

**Thioredoxin Cleaves the V3 Domain Cys296-Cys331 Disulfide Bond**—The disulfide bond cleaved in gp120 by C35STrx was determined by mass spectrometry analysis of the gp120-C35STrx complex. The key to the success of this approach was deglycosylation of the gp120 in the complex (Fig. 4A). This was required to enable accurate prediction of chymotryptic fragment masses. The tandem mass spectrum of the gp120 peptide containing the unpaired (labeled with iodoacetamide) cysteine at position 331 (residues 318–333) is shown in Fig. 4B, and the veracity of detection of this peptide is shown in Fig. 4C. The 318–333 residue peptide containing unpaired Cys331 was only and always found in the digest of the gp120-C35STrx complex. It was not observed in digests of gp120 alone. Moreover, no other carboamidomethylcysteinyl-containing peptides were detected in either sample. As controls, the relative abundance of two other unlabeled cysteine-containing peptides were found to be comparable. This result indicates that the Cys296-Cys331 disulfide bond that constrains the V3 domain of gp120 is cleaved by thioredoxin.

**V3 Domain Disulfide Bond Is Intact in Mature gp160 and Not Cleaved by Thioredoxin**—We sought to confirm that the Cys296-Cys331 disulfide bond was intact in mature gp160 by ablating the bond by mutagenesis and measuring processing to gp120 and trapping with C35STrx. HEK cells were transiently transfected with either wild type or C296A,C331A mu-
The C126A,C196A and C385A,C418A mutant gp160s were also expressed and tested. The Cys126-Cys196 disulfide bond straddles the V1 and V2 domains, whereas the Cys385-Cys418 bond constrains the V4 domain. The wild type and C126A,C196A mutant gp160 were processed to gp120 and reacted with C35STrx (Fig. 5). Neither

**FIGURE 2.** Binding of gp120 to sCD4 enhances cleavage of the gp120 disulfide bond by thioredoxin. A, HIV-1Bal gp120 was coated onto ELISA plate wells and incubated without or with wtTrx (4 μM) and/or sCD4 (4 μM) for discreet times up to 20 min. The reduced disulfide thiols in gp120 were alkylated with a biotin-linked maleimide, which was then detected using avidin-peroxidase. Trx reduced one or more disulfide bonds in gp120, which was enhanced by sCD4 (p < 0.001). The bars and errors are the mean ± S.D. of three experiments. B, C35STrx (4 μM) was incubated with HIV-1Bal gp120 (4 μM) in the absence or presence of sCD4 (4 μM) for 60 min at 25 °C. Samples of the reactions were resolved on SDS-PAGE under nonreducing conditions and blotted with anti-gp120 polyclonal antibodies. Disulfide-linked gp120-Trx complex and gp120 are indicated. The positions of Mr markers are shown at left. Formation of the gp120-Trx complex was enhanced by the presence of sCD4.

**FIGURE 3.** Thioredoxin cleaves the gp120 disulfide bond on the cell surface and cleavage is enhanced by CD4-expressing cells. A, HEK cells were transiently transfected with either full-length HIV-1 89.6 env or CD4. The gp120-expressing cells were incubated with C35STrx (4 μM) in the absence or presence of CD4-expressing cells for 60 min at 37 °C. The reaction was quenched with iodoacetamide, cell lysates prepared, and samples resolved on SDS-PAGE under nonreducing conditions and blotted with anti-Trx (left) or anti-gp120 (right) polyclonal antibodies. Disulfide-linked gp120-Trx complex, unprocessed gp160, and gp120 are indicated. The positions of Mr markers are shown at left. Formation of the gp120-Trx complex was enhanced by the presence of CD4-expressing cells. B, effect of wtTrx or C35STrx on the fusion of HEK cells expressing CXCR4 chemokine receptor and CD4 with HEK cells expressing HIV-1 89.6 env. Fusion is represented by relative luciferase units. The bars and errors are the mean ± S.E. of three separate experiments. There was no fusion of control HEK cells not expressing gp120 or CD4.
the C296A, C331A, or C385A, C418A gp160 mutant, however, was processed to gp120. These disulfide bonds, therefore, are required for host cell subtilisin processing of gp160. This is presumably due to a requirement for these bonds for correct folding and/or stability of gp160.

**DISCUSSION**

The HIV-1 env complex consists of a trimer of surface-exposed gp120 subunits that are associated with a trimer of gp41 transmembrane subunits. The binding of gp120 to cell surface CD4 leads to the creation of a binding site for a chemokine receptor, usually CCR5 and/or CXCR4. The interaction between gp120 and these cellular receptors initiates conformational changes in the gp120-gp41 complex, triggering the refolding of gp41 into a fusion-active state.

gp120 comprises five hypervariable regions (V1–V5) that alternate with conserved (C1–C5) regions (25, 26). The gp120 core consists of residues from C1 to C5 forming a conserved inner domain and a less conserved highly glycosylated outer domain. The inner and outer domains are linked through four antiparallel β-strands known as the bridging sheet. The V1–V4 hypervariable regions are excluded from the core domain by disulfide bridges, forming mobile solvent-exposed loops (27).

CD4 and chemokine receptor binding sites are juxtaposed and in close proximity to the bridging sheet, and the V1/V2 and V3 loops. The current understanding is that attachment of CD4 to gp120 leads to a reorganization of the V1/V2 and V3 loops and the formation of the chemokine receptor binding site (25). The chemokine receptor preference of HIV is determined largely by V3 sequences. The CCR5 to CXCR4 switch is generally associated with increased positive charge...
in V3, often in conjunction with sequence changes in V1/V2 and C4 (20, 28).

The gp120 disulfide bond cleaved by thioredoxin is that which constrains the V3 loop of gp120, Cys296-Cys331 (Fig. 6A). The finding of the unpaired cysteine thiol at Cys331 in the C35STrx-gp120 complex informs the mechanism of cleavage. The Cys32 sulfur ion nucleophile of thioredoxin attacks the Cys296 sulfur ion electrophile of the Cys296-Cys331 disulfide bond, cleaving the bond. The TrxCys32-Cys296gp120 mixed disulfide then spontaneously decomposes via an intramolecu-
lar thiol-disulfide exchange releasing oxidized thioredoxin (Fig. 6B). Interestingly, a recombinant gp140 trimer was found to be disulfide-bonded through the V3 domain (29), which supports the redox activity of the V3 bond.

Binding of purified sCD4 to isolated gp120 or cell surface CD4 to cell surface gp120 enhanced cleavage of the V3 disulfide bond. This result implies that CD4 binding induces a conformational change in gp120 that facilitates reduction of the disulfide bond. This conclusion is supported by the studies of Liu et al. (24), who investigated the three-dimensional structures of trimeric env displayed on native HIV-1 in the unliganded state and in complex with CD4. They showed that CD4 binding results in a major reorganization of the env trimer, causing an outward rotation and displacement of each gp120 monomer. This was coupled with a rearrangement of the gp41 trimer, leading to closer contact between the viral and target cell membranes.

We propose the following sequence of events for the contribution of the redox change in gp120 to the mechanism of HIV entry. Binding of HIV gp120 to immune cell CD4 both brings gp120 close to a cell surface oxidoreductase, which could be protein disulfide isomerase (3, 4), thioredoxin (8), or glutaredoxin-1 (13), and induces a conformational change in gp120 that facilitates reduction of the V3 domain disulfide bond by the oxidoreductase. Cleavage of the V3 disulfide bond then results in a conformational change in this domain, which triggers dissociation of chemokine receptor from gp120 and allows refolding of gp41 and viral-membrane fusion.

The observations of Barbouche et al. (3) are noteworthy in light of this model. These investigators incubated purified gp120 with the chemical reductant, β-mercaptoethanol, and then measured binding of the reduced gp120 to CD4 and also indirectly to CXCR4 by competition for binding by the CXCR4 ligand, SDF1-α. They found that gp120 containing two unpaired cysteine thiols (one cleaved disulfide bond) bound to CD4 but was less effective than native gp120 at competing for binding of SDF1-α to CXCR4. This finding implies that cleavage of the gp120 disulfide bond reduces the affinity of the protein for CXCR4, but not for CD4. It cannot be assumed that the V3 disulfide bond was the one cleaved by β-mercaptoethanol, however, so this conclusion must be treated with caution with respect to the findings reported herein. For example, the CD4 Cys150-Cys159 V3 disulfide bond is cleaved by thioredoxin, but not by the chemical reductant, dithiothreitol (7).

The V3 disulfide bond has all the hallmarks of an allosteric bond and, notably, has the same configuration as the disulfide bond cleaved in CD4. Allosteric disulfides are defined as bonds that control the function of the mature protein when they are reduced or oxidized (30, 31). A feature of the allosteric disulfides identified so far is that they link β-strands or β-loops (32). They have also been associated with a particular disulfide bond configuration known as the –RHStaple, which reflects the sign of the five χ (chi) angles that make up the disulfide bond (30). There are 20 possible disulfide bond configurations based on this measure. A particular property of –RHStaple bonds is the close proximity of the α-carbon atoms of the two cysteine residues (30).

The Cys206-Cys331 V3 disulfide bond is an –RHStaple in all eight crystal structures of gp120 in the Protein Data Bank (31). It constrains a β-loop motif (Fig. 6B) and has a very short α-carbon–α-carbon distance of 3.84 ± 0.04 Å (mean ± S.E. for the eight structures), compared with a mean of 5.62 Å for all disulfides in a nonredundant set of x-ray structures (31) (Fig. 6A). The disulfide bond cleaved in CD4, Cys130-Cys159 in domain 2, is also an –RHStaple that links adjacent β-strands and has a short α-carbon–α-carbon distance of 3.3 Å (7, 33).

The fact that the functional disulfides in both CD4 and gp120 have the same unusual configuration likely reflects some common requirement for their reduction. Disulfide bond reduction occurs via a bimolecular nucleophilic substitution (S₂), reaction mechanism (34, 35). This reaction is highly directional and proceeds via a transition state in which the three sulfur atoms involved, in this case the Cys32 sulfur nucleophile of thioredoxin and the two sulfur atoms of the gp120 or CD4 disulfide bond, must form a ~180° angle (Fig. 6B). Steric factors that prevent proper positioning of the three sulfur atoms will preclude any reaction. It may be that the –RHStaple configuration provides for the correct positioning of the three sulfur atoms involved.

The nature of the conformational change in the V3 domain upon reduction of the disulfide bond is not known but may be similar to that observed for cleavage of an analogous –RHStaple bond in the plant peptidyl-prolyl cis-trans isomerase, AtFKBP13. Photosynthesis in plants and eukaryotic algae occurs in the chloroplasts and the lumen of these organelles, the thylakoids, is the site of oxygen evolution. There are more than a dozen resident peptidyl-prolyl cis-trans isomerases in the thylakoid lumen, one of which is AtFKBP13. The enzyme contains an –RHStaple disulfide bond (Cys106-Cys361) that is reduced by chloroplast m-type thioredoxin (36). Cleavage of the bond results in loss of peptidyl-prolyl isomerase activity. The disulfide links a β-loop motif that shifts position considerably when the bond is reduced (Fig. 6C).

Strategies to prevent cleavage of the gp120 V3 disulfide bond will inhibit HIV infection. This has been achieved in vitro by inactivating the oxidoreductase(s) responsible for the cleavage of the V3 bond (3–6, 8, 13). Another means of intervention might be dithiol cross-linking agents that react with the unpaired Cys206 and Cys331 thiols and prevent the conformational change in the V3 domain.

Acknowledgment—We thank Dr. Pantelis Pounourios for the HIV molecular clone that was used to create the env expression vector.

REFERENCES
1. Einfeld, D. (1996) Curr. Top. Microbiol. Immunol. 214, 133–176
2. Gallo, S. A., Finnegan, C. M., Viard, M., Raviv, Y., Dimitrov, A., Rawat, S. S., Puri, A., Durell, S., and Blumenthal, R. (2003) Biochim. Biophys. Acta 1614, 36–50
3. Barbouche, R., Miquelis, R., Jones, I. M., and Fenouillet, E. (2003) J. Biol. Chem. 278, 3131–3136
4. Gallina, A., Hanley, T. M., Mandel, R., Trahey, M., Broder, C. C., Viglianti, G. A., and Ryser, H. J. (2002) J. Biol. Chem. 277, 50579–50588
5. Markovic, I., Stantchev, T. S., Fields, K. H., Tiffany, L. J., Tomic, M., Weiss, C. D., Broder, C. C., Strebel, K., and Clouse, K. A. (2004) Blood 103, 1586–1594
gp120 V3 Domain Disulfide Is Cleaved by Thioredoxin

6. Ryser, H. J., Levy, E. M., Mandel, R., and DiSciullo, G. J. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 4559–4563

7. Matthias, L. I., Yam, P. T., Jiang, X. M., Vandegraaff, N., Li, P., Pombourgios, P., Donoghue, N., and Hogg, P. J. (2002) Nat. Immunol. 3, 727–732

8. Ou, W., and Silver, J. (2006) Virology 350, 406–417

9. Schwertassek, U., Balmer, Y., Gutscher, M., Weingarten, L., Preuss, M., Engelhard, J., Winkler, M., and Dick, T. P. (2007) EMBO J. 26, 3086–3097

10. Maekawa, A., Schmidt, B., Fazekas de St. Groth, B., Sanejouand, Y. H., and Hogg, P. J. (2006) J. Immunol. 176, 6873–6878

11. Sanejouand, Y. H. (2004) Proteins 57, 205–212

12. Bourgeois, R., Mercier, J., Paquette-Brooks, I., and Cohen, E. A. (2006) Retrovirology 3, 31

13. Auwerx, J., Isacsson, O., Söderlund, J., Balzarini, J., Johansson, M., and Lundberg, M. (2009) Int. J. Biochem. Cell Biol. 41, 1269–1275

14. Jiang, X. M., Fitzgerald, M., Grant, C. M., and Hogg, P. J. (1999) J. Biol. Chem. 274, 2416–2423

15. Lundström, I., and Holmgren, A. (1993) Biochemistry 32, 6649–6655

16. Tagaya, Y., Maeda, Y., Mitsui, A., Kondo, N., Matsu, H., Hamuro, J., Brown, N., Araki, K., Yokota, T., Wakasug, H., et al. (1989) EMBO J. 8, 757–764

17. Schwertassek, U., Weingarten, L., and Dick, T. P. (2007) Sci. STKE 2007, pl8

18. Stathakis, P., Lay, A. J., Fitzgerald, M., Schlieker, C., Matthias, L. I., and Hogg, P. J. (1999) J. Biol. Chem. 274, 8910–8916

19. Collman, R., Balliet, J. W., Gregory, S. A., Friedman, H., Kolson, D. L., Nathanson, N., and Srinivasan, A. (1992) J. Virol. 66, 7517–7521

20. Pombourgios, P., Maerz, A. L., and Drummer, H. E. (2003) J. Biol. Chem. 278, 42149–42160

21. Maerz, A. L., Drummer, H. E., Wilson, K. A., and Pombourgios, P. (2001) J. Virol. 75, 6635–6644

22. Deng, H., Liu, R., Ellineier, W., Choe, S., Unutmaz, D., Burkhart, M., Di Marzio, P., Marmon, S., Sutton, R. E., Hill, C. M., Davis, C. B., Peiper, S. C., Schall, T. J., Littman, D. R., and Landau, N. R. (1996) Nature 381, 661–666

23. Moss, B., Elroy-Stein, O., Mizukami, T., Alexander, W. A., and Fuerst, T. R. (1990) Nature 348, 91–92

24. Liu, J., Bartesaghi, A., Borgnia, M. J., Sapiro, G., and Subramaniam, S. (2008) Nature 455, 109–113

25. Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., and Hendrickson, W. A. (1998) Nature 393, 648–659

26. Kwong, P. D., Wyatt, R., Majeed, S., Robinson, J., Sweet, R. W., Sodroski, J., and Hendrickson, W. A. (2000) Structure 8, 1329–1339

27. Leonard, C. K., Spellman, M. W., Riddle, L., Harris, R. J., Thomas, J. N., and Gregory, T. J. (1990) J. Biol. Chem. 265, 10373–10382

28. Hoffman, N. G., Seilier-Moiseiwitsch, F., Ahn, J., Walker, J. M., and Swanstrom, R. (2002) J. Virol. 76, 3852–3864

29. Billington, J., Hickling, T. P., Munro, G. H., Halai, C., Chung, R., Dodson, G. G., and Daniels, R. S. (2007) J. Virol. 81, 4604–4614

30. Schmidt, B., Ho, L., and Hogg, P. J. (2006) Biochemistry 45, 7429–7433

31. Schmidt, B., and Hogg, P. J. (2007) BMC Struct. Biol. 7, 49

32. Azimi, I., Wong, J. W. H., and Hogg, P. J. (2010) Antioxid. Redox Signal., in press

33. Wouters, M. A., Lau, K. K., and Hogg, P. J. (2004) Bioessays 26, 73–79

34. Fernandes, P. A., and Ramos, M. J. (2004) Chemistry 10, 257–266

35. Wita, A. P., Perez-Jimenez, R., Walther, K. A., Gräter, F., Berne, B. J., Holmgren, A., Sanchez-Ruiz, J. M., and Fernandez, J. M. (2007) Nature 450, 124–127

36. Gopalan, G., He, Z., Balmer, Y., Romano, P., Gupta, R., Héroux, A., Buchanan, B. B., Swaminathan, K., and Luan, S. (2004) Proc. Natl. Acad. Sci. U.S.A. 101, 13945–13950

37. Huang, C. C., Stricher, F., Martin, L., Decker, J. M., Majeed, S., Barthe, P., Hendrickson, W. A., Robinson, J., Roumen, C., Sodroski, J., Wyatt, R., Shaw, G. M., Vita, C., and Kwong, P. D. (2005) Structure 13, 755–768